Evgeny Ishmuratov

Dr. Evgeny Ishmuratov

V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
GSGonzalo P. Solis
Gonzalo P. Solis
TKTatyana Kozhanova
Tatyana Kozhanova
AKAlexey Koval
Alexey Koval
SZSvetlana S. Zhilina
Svetlana S. Zhilina
TMTatyana I. Mescheryakova
Tatyana I. Mescheryakova
Vladimir KatanaevVladimir Katanaev
Vladimir Katanaev
Heterotrimeric G proteins are immediate transducers of G protein-coupled receptors—the biggest receptor family in metazoans—and play innumerate functions in health and disease. A set of de novo point mutations in GNAO1 and GNAI1, the genes encoding the α-subunits (Gαo and Gαi1, respectively) of the heterotrimeric G proteins, have been described to cause pediatric encephalopathies represented by epileptic seizures, movement disorders, developmental delay, intellectual disability, and signs of neurodegeneration. Among such mutations, the Gln52Pro substitutions have been previously identified in GNAO1 and GNAI1. Here, we describe the case of an infant with another mutation in the same site, Gln52Arg. The patient manifested epileptic and movement disorders and a developmental delay, at the onset of 1.5 weeks after birth. We have analyzed biochemical and cellular properties of the three types of dominant pathogenic mutants in the Gln52 position described so far: Gαo[Gln52Pro], Gαi1[Gln52Pro], and the novel Gαo[Gln52Arg]. At the biochemical level, the three mutant proteins are deficient in binding and hydrolyzing GTP, which is the fundamental function of the healthy G proteins. At the cellular level, the mutants are defective in the interaction with partner proteins recognizing either the GDP-loaded or the GTP-loaded forms of Gαo. Further, of the two intracellular sites of Gαo localization, plasma membrane and Golgi, the former is strongly reduced for the mutant proteins. We conclude that the point mutations at Gln52 inactivate the Gαo and Gαi1 proteins leading to aberrant intracellular localization and partner protein interactions. These features likely lie at the core of the molecular etiology of pediatric encephalopathies associated with the codon 52 mutations in GNAO1/GNAI1.

16 April 2024 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
Evgeny IshmuratovEvgeny Ishmuratov
Evgeny Ishmuratov
AZA. A. Zuev
A. A. Zuev
Success of surgically treated epilepsy depends on the accuracy of epileptogenic zone localization. Single-photon emission computed tomography (SPECT) using SISCOM (subtraction ictal SPECT co-registered to MRI) protocol is the only imaging method that allows identification of ictal onset zone by injection and fixation of a special radioactive tracer in the area of increased cerebral blood flow. The review outlines the key stages of SPECT using SISCOM protocol, generalizes and analyzes data for related opportunities and disadvantages as well as its prospects for use in preoperative examination of patients with epilepsy. It was demonstrated that the technique showed high sensitivity (mean 70–75%) to localize epileptogenic zone in patients with pharmacoresistant epilepsy in case if brain structural changes were not detected by magnetic resonance imaging (MRI). However, the organizational features of the procedure in combination with its specific limitations for epilepsy patients do not allow it to be considered as a routine diagnostic method.

2 May 2025 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
AUA. A. Utyasheva
A. A. Utyasheva
NINikita Olegovich Ivin
Nikita Olegovich Ivin
Evgeny IshmuratovEvgeny Ishmuratov
Evgeny Ishmuratov
NUN. P. Utyashev
N. P. Utyashev
EGE. А. Gordeyeva
E. А. Gordeyeva
AZA. A. Zuev
A. A. Zuev
Background. Epilepsy surgery is mainly aimed at removing patient seizures. Despite the high efficiency of surgical treatment, a search for probable predictors of adverse outcomes and the analysis of the quality of life (QoL) in patients attempted to be surgically assisted provide only partial relief from disturbing paroxysms remain relevant.Objective: To comprehensively assess disease parameters in post-surgery patients with focal drug-resistant epilepsy (DRE) with incomplete remission (Engel II–IV outcomes), and to identify QoL prognostic factors.Material and methods. A single-center, retrospective, observational study assessing 67 patients with incomplete remission (Engel II–IV outcomes) operated for focal DRE was carried out. The following disease parameters identified as potentially possible QoL predictors after surgical treatment were analyzed: seizure frequency and severity post-surgery; dominance of the brain hemisphere underwent surgery; pre-surgery seizure type; neurological deficit post-surgery; epileptogenic substrate morphology; resection zone; extent of resection; disease duration.Results. In patients with Engel II–IV surgery outcomes, a quite high level of positive subjective self-assessment condition (52,2%) was revealed, with number of seizures reduced by at least 50% in 59,7% cases. A statistically significant influence on the positive subjective QoL assessment based on criteria such as decreased frequency and strength of seizures after surgery (p<0,001) was found. Tailored resection of the epileptogenic zone led to aggravated seizure severity and frequency outcomes. Lobectomies and disconnection operations in 45,7% cases were accompanied by reduced number of seizures by at least 75%. Temporal lobe surgeries, compared with extratemporal resections, were more often correlated with QoL improvement.Conclusion. In most cases, DRE surgical treatment leads to lower seizure rate and significantly improved QoL, even in the case of incomplete remission. Seizure frequency and severity post-surgery were the only parameters affecting postsurgical QoL in patients with incomplete remission.